---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-113158"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:03:22.150470+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights

## Summary
- Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.
- Cash & equivalents $3.3M; plans to raise additional capital.
- R&D expense $11.9M, G&A $18.2M; stock-based compensation $11.8M.
- FDA approved LYMPHIR (denileukin diftitox-cxdl) for CTCL; commercial launch expected H1 2025.
- Completed Citius Oncology spin-off (CTOR) on Nasdaq in August 2024.

## SEC filing metadata
- accession: 0001213900-24-113158
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/0001213900-24-113158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024113158/ea0226161-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-113158
- JSON: https://secwatch.observer/filing/0001213900-24-113158.json
- Plain text: https://secwatch.observer/filing/0001213900-24-113158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.